wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37329579-05B0A10E-74AA-4EC3-A40D-A319FB378139
Q37329579-05B0A10E-74AA-4EC3-A40D-A319FB378139
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37329579-05B0A10E-74AA-4EC3-A40D-A319FB378139
Post-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.
P2860
Q37329579-05B0A10E-74AA-4EC3-A40D-A319FB378139
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37329579-05B0A10E-74AA-4EC3-A40D-A319FB378139
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e3928e6d3c76707ee0eb113c5ea5be01938daf10
P2860
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.